BRIEF—Executive leadership changes at Purple Biotech

Israel-based Purple Biotech today announced the decision by Isaac Israel, former chief executive to step down from his CEO role and reduce the scope of his engagement with the company for personal reasons, effective July 10, 2022.

Gil Efron, will assume the role of chief executive on that date.

Isaac Israel will continue his involvement in the company as an advisor and as a member of the board of directors.

Mr Efron has served as president and chief financial officer of Purple Biotech since June 2021.

Prior to that, he served as deputy CEO and CFO, having joined the company in 2018.

Formerly, he served as deputy CEO and CFO of Kamada, a NASDAQ and TASE dual-listed therapeutics company, from September 2011 to November 2017.